---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-066245"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:06:08.920155+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology appoints Ken Kobayashi as Chief Medical Officer effective Nov 27, 2023

## Summary
- Ken Kobayashi appointed CMO effective Nov 27, 2023; will lead clinical and regulatory operations.
- Dr. Kobayashi has over 25 years of oncology drug development experience, including at Pfizer, Daiichi Sankyo, and AstraZeneca.
- Employment terms: $500k base salary, 40% target bonus; inducement grant of options for 1.25% of outstanding shares.
- Options vest over 4 years with 25% on 1st anniversary, then monthly; additional 0.25% vesting on milestones.
- Severance: 9 months base salary and health coverage if terminated without cause or for good reason.

## SEC filing metadata
- accession: 0000950170-23-066245
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023066245/0000950170-23-066245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023066245/pyxs-20231127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-066245
- JSON: https://secwatch.observer/filing/0000950170-23-066245.json
- Plain text: https://secwatch.observer/filing/0000950170-23-066245.txt

## Key facts
- Executive change
  Ken Kobayashi was appointed as Chief Medical Officer at Pyxis Oncology, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On November 28, 2023, Pyxis Oncology, Inc. (the “Company”) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017023066245/0000950170-23-066245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.